CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Aztreonam for inhalation solution

Last Updated: December 2, 2010
Result type: Reports
Project Number: SR0220-000
Product Line: Reimbursement Review

Generic Name: Aztreonam for inhalation solution

Brand Name: Cayston

Manufacturer: Gilead Sciences Canada Inc.

Therapeutic Area: Cystic fibrosis, chronic pulmonary pseudomonas aeruginosa infections

Indications: Cystic fibrosis (CF) with chronic pulmonary pseudomonas aeruginosa infections

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: July 18, 2011

Recommendation Type: List with clinical criteria and/or conditions